Niki BioSolutions, Inc. (NIKI) stock
NIKINasdaqMeasuring & Controlling Devices, NECFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2025, quý kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 4/30
$1.60+0.10 (+6.67%)
Close on Nov 18, 2026Market cap $13.03MP/E –Yield –
Niki BioSolutions r&d expenses
Research and development expenses are spending on new products and technology.
Niki BioSolutions's R&D Expenses for the twelve months ending Dec 31, 2025 was $352.88K. For fiscal 2025 it was $352.88K, down 83.9% from the year before. The highest annual figure on record is $11.59M in fiscal 2020.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $352.88K | -83.9% |
| FY2024 | Dec 31, 2024 | $2.20M | -57.8% |
| FY2023 | Dec 31, 2023 | $5.20M | -43.6% |
| FY2022 | Dec 31, 2022 | $9.22M | -15.2% |
| FY2021 | Dec 31, 2021 | $10.87M | -6.2% |
| FY2020 | Dec 31, 2020 | $11.59M | +67.0% |
| FY2019 | Dec 31, 2019 | $6.94M | +123.7% |
| FY2018 | Dec 31, 2018 | $3.10M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $91.71K | – |
| Q3 FY2025 | Sep 30, 2025 | $241.79K | – |
| Q3 FY2024 | Sep 30, 2024 | $440.70K | – |
See a number that looks wrong?